RCM Tech | 8-K: FY2025 Q2 Revenue Misses Estimate at USD 78.17 M

Revenue: As of FY2025 Q2, the actual value is USD 78.17 M, missing the estimate of USD 80.42 M.

EPS: As of FY2025 Q2, the actual value is USD 0.5, missing the estimate of USD 0.54.

EBIT: As of FY2025 Q2, the actual value is USD 5.672 M.

Segment Revenue

• Specialty Health Care: Revenue for the thirteen weeks ended June 28, 2025, was $42.8 million, compared to $36.9 million for the same period in 2024.
• Engineering: Revenue for the thirteen weeks ended June 28, 2025, was $26.5 million, compared to $22.5 million for the same period in 2024.
• Life Sciences, Data and Solutions: Revenue for the thirteen weeks ended June 28, 2025, was $8.8 million, compared to $9.7 million for the same period in 2024.

Operational Metrics

• Net Income: GAAP net income for the thirteen weeks ended June 28, 2025, was $3.8 million, compared to $3.8 million for the same period in 2024.
• Gross Margin: Gross profit margin for the thirteen weeks ended June 28, 2025, was 28.5%, compared to 28.9% for the same period in 2024.
• Operating Income: Operating income for the thirteen weeks ended June 28, 2025, was $6.6 million, compared to $5.8 million for the same period in 2024.
• Operating Margin: Operating margin for the thirteen weeks ended June 28, 2025, was 8.4%, compared to 8.4% for the same period in 2024.

Cash Flow

• Operating Cash Flow: Net cash used in operating activities for the thirteen weeks ended June 28, 2025, was - $7.9 million, compared to $5.7 million provided by operating activities for the same period in 2024.

Unique Metrics

• Adjusted EBITDA: Adjusted EBITDA for the thirteen weeks ended June 28, 2025, was $8.1 million, compared to $7.2 million for the same period in 2024.

Outlook / Guidance

• The company expects continued growth across all segments, with a strong second half of the year anticipated.